Clinical effect and safety of dexmedetomidine combined with sufentanil and propofol in painless gastroscopy for obese patients
-
摘要:
目的探讨右美托咪定复合舒芬太尼与异丙酚用于肥胖患者无痛胃镜检查的临床应用效果和安全性。 方法将拟行无痛胃镜检查的136例肥胖患者随机分为观察组(以右美托咪定复合舒芬太尼和异丙酚为麻醉方案)与对照组(以舒芬太尼复合异丙酚为麻醉方案),每组各68例。观察组男37例,女31例,年龄44.6±8.5岁;对照组男39例,女29例,年龄43.2±6.8岁。比较两组麻醉效果、诱导时间、检查时间、苏醒时间、定向力恢复时间及异丙酚用量。观察两组患者麻醉诱导前(T0)、入镜时(T1)、镜体至会厌水平时(T2)、术毕时(T3)、术毕后5 min(T4)等时间点平均动脉压、心率、呼吸频率的变化。检测两组T0、T4时皮质醇、去甲肾上腺素等应激指标浓度水平,记录围术期不良反应,并调查内镜医师、麻醉医师及患者满意度。 结果观察组麻醉优良率为92.65%,高于对照组的72.06%(P<0.05)。观察组诱导时间、苏醒时间、定向力恢复时间短于对照组(P<0.05),异丙酚用量低于对照组(P<0.05)。对照组T1、T2、T3 时平均动脉压、心率、呼吸频率的变化程度大于观察组(P<0.05)。与T0时比较,两组T4时皮质醇、去甲肾上腺素水平增高,但观察组增加程度低于对照组(P<0.05)。观察组体动、呛咳、呼吸抑制、低血压的发生率低于对照组(P<0.05)。观察组的内镜医师满意度、麻醉医师满意度及患者满意度高于对照组。 结论右美托咪定复合舒芬太尼与异丙酚用于肥胖患者无痛胃镜检查,麻醉效果好,患者术中生命体征稳定,不良反应少。 Abstract:ObjectiveTo investigate the clinical effect and safety of dexmedetomidine combined with sufentanil and propofol in painless gastroscopy for obese patients. MethodsA total of 136 obese patients who were to undergo painless gastroscopy were randomly divided into group D (with dexmedetomidine combined with sufentanil and propofol as the anesthetic regimen) and group C (with sufentanil combined with propofol as the anesthetic regimen), with 68 cases each. There were 37 males and 31 females with an average age of 44.6±8.5 in observation group, 39 males and 29 females with an average age of 43.2±6.8 in control group. The anesthetic effect, induction time, examination time, waking time, directional force recovery time and propofol dosage were compared between the two groups. The changes of mean arterial pressure (MAP), heart rate (HR) and respiratory rate (RR) in two groups were observed before the induction of anesthesia (T0), at the time of endoscopic induction (T1), from the endoscopic body to the level of epiglottis (T2), at the end of operation (T3), and 5 min after operation (T4). The stress indicators such as cortisol (Cor) and norepinephrine (NA) at T0 and T4 were measured. The perioperative adverse reactions were recorded. The satisfaction of endoscopists, anesthesiologists and patients were investigated. ResultsThe excellent and good rate of anesthesia in group D was higher than that in group C (92.65% vs 72.06%, P<0.05).The induction time, awakening time and directional force recovery time of group D were shorter than that of group C (P<0.05), and the dosage of propofol was lower than that of group C (P<0.05).The changes of MAP, HR and RR in group C at T1, T2 and T3 were significantly greater than those in group D (P<0.05). Compared with T0, Cor and NA levels in the two groups increased in T4, but the degree of increase in group D was lower than that in group C (P<0.05). The incidences of body movement, cough, respiratory depression and hypotension in group D were lower than that in group C (P<0.05).The satisfaction of endoscopists, anesthesiologists and patients in group D was higher than that in group C. ConclusionFor painless gastroscopy in obese patients, the dexmedetomidine combined with sufentanil and propofol have good anesthetic effect, stable intraoperative vital signs and few adverse reactions. -
Key words:
- gastroscope /
- obesity /
- dexmedetomidine /
- sufentanil /
- propofol /
- anesthesia /
- stress
-
表 1 两组患者基线资料比较(n=68)
Table 1. Comparison of baseline data between two groups
组别 性别(n) 年龄(岁,Mean±SD) ASA 分级(n) BMI(kg/m2,Mean±SD) 合并症(n) 男 女 Ⅰ Ⅱ 高血压 糖尿病 观察组 37 31 44.6±8.5 41 27 33.6±2.7 29 7 对照组 39 29 43.2±6.8 43 25 32.9±1.6 25 9 表 2 两组麻醉效果比较[n=68, n(%)]
Table 2. Comparison of anesthetic effect between two groups
组别 优 良 一般 差 优良率 观察组 49(72.1) 14(20.6) 5(7.4) 0(0.0) 63(92.65)* 对照组 38(55.9) 11(16.2) 16(23.5) 3(4.4) 49(72.06) *P<0.05 vs 对照组. 表 3 两组诱导时间、检查时间、苏醒时间、定向力恢复时间、异丙酚用量比较(n=68,Mean±SD)
Table 3. Comparison of induction time, examination time, recovery time, directional force recovery time and propofol dosage between the two groups
组别 诱导时间(min) 检查时间(min) 苏醒时间(min) 定向力恢复时间(min) 异丙酚用量(mg) 观察组 1.18±0.26* 4.15±1.59 1.65±0.48* 5.46±0.76* 109.4±16.5* 对照组 2.09±0.48 4.46±0.81 4.96±1.39 8.79±1.45 179.8±21.7 *P<0.05 vs 对照组. 表 4 两组血流动力学指标变化的差异(n=68,Mean±SD)
Table 4. The difference of hemodynamic indexes between the two groups
指标 组别 T0 T1 T2 T3 T4 MAP(mmHg) 观察组 73.8±8.6 76.2±9.0* 72.1±8.7* 70.2±8.5* 74.6±9.2 对照组 73.6±8.3 66.5±9.8 69.3±9.7 67.3±9.5 76.5±9.1 HR(次/min) 观察组 76.3±9.0 73.6±8.6* 73.9±8.7* 73.6±9.3* 74.0±8.3 对照组 74.0±7.9 66.4±9.1 80.3±10.4 68.6±9.4 76.7±9.6 RR(次/min) 观察组 17.9±3.0 16.7±3.2* 17.1±2.8* 16.8±2.9* 16.9±2.7 对照组 17.8±3.1 14.1±2.7 14.9±3.0 15.0±2.6 17.1±2.9 *P<0.05 vs 对照组; MAP: 平均动脉压; HR: 心率; RR: 呼吸频率. 表 5 两组患者T0、T4时Cor、NA血浆水平比较(n=68,Mean±SD)
Table 5. Cor、NA plasma levels at T0、T4 in two groups
组别 Cor(ng/mL) NA(ng/L) T0 T4 T0 T4 观察组 183.71±16.40 216.79±19.14*# 176.33±30.45 346.81±48.09*# 对照组 181.63±17.68 239.86±20.37* 178.65±30.26 390.96±50.76* *P<0.05 vs本组T0;#P<0.05 vs对照组同时间点. 表 6 两组患者不良反应比较[n=68, n(%)]
Table 6. Comparison of adverse reactions between two groups
组别 喉痉挛 体动 呛咳 恶心呕吐 呼吸抑制 低血压 心动过缓 头晕 舌后坠 观察组 0(0.0) 1(1.5)* 1(1.5)* 1(1.5) 1(1.5)* 2(2.9)* 3(4.4) 2(2.9) 0(0.0) 对照组 0(0.0) 7(10.3) 6(8.8) 3(4.4) 5(7.4) 7(10.3) 1(1.5) 5(7.4) 0(0.0) *P<0.05 vs 对照组. 表 7 两组内镜医师、麻醉医师及患者满意度比较(n=68,Mean±SD)
Table 7. Comparison of the satisfaction of endoscopic physicians, anesthesiologists and patients in two groups
组别 内镜医师满意度 麻醉医师满意度 患者满意度 观察组 9.31±1.27* 9.05±0.96* 9.48±1.06* 对照组 8.65±1.09 7.76±0.82 7.29±0.55 *P<0.05 vs 对照组. -
[1] 蒋 凌, 唐 文, 周维霞, 等. 肥胖对无痛胃镜检查患者呼吸循环功能及苏醒质量的影响分析[J]. 中国医学前沿杂志:电子版, 2017, 9(10): 58-61. [2] 夏江燕, 陆新健, 袁 静, 等. 丙泊酚复合阿片类药物在胃镜检查中的应用[J]. 临床麻醉学杂志, 2016, 32(5): 464-7. [3] Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial[J]. Paediatr Anaesth, 2014, 24(2): 181-9. doi: 10.1111/pan.12287 [4] 杨文荣, 丁泽君, 杨洪光, 等. 舒芬太尼联合右美托咪定对胸科手术术后镇痛的效果观察[J]. 中国医药, 2016, 11(6): 861-4. doi: 10.3760/cma.j.issn.1673-4777.2016.06.020 [5] 王师军, 田 旭, 陈伟庆, 等. 不同时间服用盐酸达克罗宁胶浆对胃镜检查效果的影响[J]. 临床与病理杂志, 2019, 39(1): 51-5. doi: 10.3978/j.issn.2095-6959.2019.01.009 [6] 赵小利, 李洁琼, 李 昊, 等. Ramsay评分对降低非计划性拔管发生率及镇静药物使用的影响[J]. 中国医药, 2016, 11(5): 698-700. doi: 10.3760/cma.j.issn.1673-4777.2016.05.019 [7] 朱 魏, 王尔华, 汪小海. 右美托咪啶复合瑞芬太尼在超声胃镜中的应用[J]. 临床药物治疗杂志, 2018, 16(12): 26-8. doi: 10.3969/j.issn.1672-3384.2018.12.006 [8] Cappell MS, Mogrovejo E, Desai T. Case report of patient presenting in shock from band penetration into stomach after LAGB surgery: diagnosis by emergency EGD after misdiagnosis by abdominal CT[J]. Dig Dis Sci, 2016, 61(11): 3366-8. doi: 10.1007/s10620-016-4287-y [9] 彭 红, 肖庆华, 李秋莲, 等. 提高老年肥胖患者行无痛胃镜检查安全性探讨[J]. 中国医学创新, 2016, 13(16): 28-31. doi: 10.3969/j.issn.1674-4985.2016.16.008 [10] 中华医学会麻醉学分会, 中华医学会消化内镜学分会. 中国消化内镜诊疗镇静/麻醉的专家共识[J]. 临床麻醉学杂志, 2014, 30(9): 920-7. [11] 帅训军, 彭霄艳, 艾登斌. 阿芬太尼复合丙泊酚对胃镜检查病人麻醉效果观察[J]. 齐鲁医学杂志, 2013, 28(2): 147-9. [12] Külling D, Fantin AC, Biro P, et al. Safer colonoscopy with patient-controlled analgesia and sedation with propofol and alfentanil[J]. Gastrointest Endosc, 2001, 54(1): 1-7. doi: 10.1067/mge.2001.116174 [13] 李 超, 田 鸣, 刘缚鲲, 等. 不同剂量舒芬太尼用于高龄患者胃镜检查清醒镇静的临床研究[J]. 临床和实验医学杂志, 2017, 16(4): 406-8. doi: 10.3969/j.issn.1671-4695.2017.04.031 [14] 郑丽花, 邵雪泉, 杨淑芬, 等. 右美托咪定清醒慢诱导用于肥胖患者气管插管的临床观察[J]. 浙江临床医学, 2014, (9): 1486-7. [15] 徐卫团, 喻文立. 右美托咪定的临床应用进展[J]. 医学综述, 2017, 23(9): 1830-4. doi: 10.3969/j.issn.1006-2084.2017.09.034 [16] 周冬梅. 按照不同体重标准使用右美托咪啶对肥胖患者进行经鼻气管插管麻醉的效果分析[J]. 当代医药论丛, 2015, 13(4): 260-1. [17] 李彦君, 张建新. 右美托咪定复合丙泊酚对高血压患者无痛胃镜检查应激反应及早期认知功能的影响[J]. 海南医学院学报, 2017, 23(17): 2445-8. [18] Meng Q T, Xia Z Y, Luo T, et al. Dexmedetomidine reduces emergence agitation after tonsillectomy in children by sevoflurane anesthesia: a case-control study[J]. Int J Pediatr Otorhinolaryngol, 2012, 76(7): 1036-41. doi: 10.1016/j.ijporl.2012.03.028 [19] 任 莉. 盐酸右美托咪定在肥胖患者体内的临床药代动力学研究[D]. 广州: 南方医科大学, 2014. [20] Cortínez LI, Anderson BJ, Holford NH, et al. Dexmedetomidine pharmacokinetics in the obese[J]. Eur J Clin Pharmacol, 2015, 71(12): 1501-8. doi: 10.1007/s00228-015-1948-2 [21] 周东旭, 徐 波, 屠伟峰, 等. 右美托咪定在不同肥胖程度患者体内药代动力学研究[J]. 暨南大学学报:自然科学与医学版, 2016, 37(3): 245-8. [22] 章冉冉, 阳国平, 裴 奇, 等. 右美托咪定在特殊人群中的药代动力学研究进展[J]. 中国临床药理学杂志, 2014, 30(7): 650-2. [23] 杜 萍, 王春平, 刘卫敬, 等. 右美托咪啶单次负荷剂量给药在肥胖患者椎管内麻醉镇静的临床观察[J]. 河北医科大学学报, 2014, 35(1): 97-9. doi: 10.3969/j.issn.1007-3205.2014.01.036 [24] 万 磊, 刘 洋, 李修良. 右美托咪定联合七氟醚吸入诱导用于病态肥胖合并重度鼾症患者喉罩置入的临床观察[J]. 临床和实验医学杂志, 2019, 18(6): 664-8. doi: 10.3969/j.issn.1671-4695.2019.06.032 [25] 冯 艳, 魏 芳. 小剂量右美托咪定联合丙泊酚在肥胖者无痛人流术中的麻醉效果观察[J]. 中国实用乡村医生杂志, 2016, 23(8): 62-4. doi: 10.3969/j.issn.1672-7185.2016.08.023 [26] 张永红, 李 月. 盐酸右美托咪复合丙泊酚用于无痛胃镜检查的临床观察[J]. 现代消化及介入诊疗, 2019, 24(5): 474-7. doi: 10.3969/j.issn.1672-2159.2019.05.006 [27] 阴 爽, 郭永民, 刘晓萍, 等. 右美托咪定喷鼻联合丙泊酚静脉注射用于成人肥胖患者无痛胃镜下黏膜切除术麻醉效果观察[J]. 山东医药, 2019, 59(2): 75-8. doi: 10.3969/j.issn.1002-266X.2019.02.022 [28] 张 浩, 刘存明. 瑞芬太尼靶控输注在过度肥胖患者无痛胃镜检查中的应用[J]. 医学研究杂志, 2017, 46(4): 154-6. doi: 10.11969/j.issn.1673-548X.2017.04.039